drugset / Trial / NCT04201275

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

NCT04201275

Phase 1 Completed 28 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity of HEC74647 in HCV treatment naïve subjects with genotypes 1-6.

Timeline

Start
2019-12-18
Primary completion
2020-01-17
Completion
2020-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC74647PA Unknown 50 mg Oral
Subject HEC74647PA Unknown 100 mg Oral
Subject HEC74647PA Unknown 200 mg Oral